Version 2 2024-06-17, 11:17Version 2 2024-06-17, 11:17
Version 1 2015-05-05, 16:01Version 1 2015-05-05, 16:01
journal contribution
posted on 2024-06-17, 11:17authored byDG Legge, DH Gleeson, H Lofgren, B Townsend
Universal access to affordable medicines, which are safe, efficacious and of high quality, and which are appropriately used, depends on national legislation that is in turn constrained by a range of international agreements. This regulatory configuration also affects the profitability of the pharmaceutical industry, domestic and international. Tensions and contradictions between industry profitability and public health objectives relate to access, innovation and regulation.